Read oxford vaccine latest news on The Economic Times. oxford vaccine updates, oxford vaccine developments, videos and more.

Achieved Q1 2026 PEMGARDA® (pemivibart) net product revenue of $13.7 million, representing 22% growth versus Q1 2025 net product revenue of $11.3 ...

CAMBRIDGE, MA / ACCESS Newswire / September 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikevax®, which targets the LP ...

Pharma and biotech stocks rallied after the WHO flagged a hantavirus outbreak linked to a cruise ship, reviving investor bets ...

An mRNA-based flu shot could make a huge difference in flu prevention, allowing scientists to pick a better strain match.

Moderna forecasts lower-than-expected Q2 revenue Moderna aims for significant share of Europe's respiratory vaccine market with 2027 mCombriax launch International sales outpace US as partnerships ...

Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Bluesky. You can reach Helen on ...

Moderna’s mRNA-based combination vaccine against both flu and COVID-19 has gotten the green light in Europe—but it continues to be shelved in the US, where it was developed. This week, the European ...

COMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's ...

Sanofi’s protein-based vaccine Nuvaxovid has conquered Moderna’s next-generation messenger RNA shot mNexspike in a head-to-head trial assessing the tolerability of the two COVID vaccines. In the phase ...

A patent dispute over technology key to messenger RNA Covid-19 vaccines is settling with Moderna agreeing to pay $950 million up front and potentially more than $1 billion later, a resolution that ...